GlaxoSmithKline
GSK
$45.46
Share price
0.63%
Change (1 day)
23.59%
Change (1 year)
Categories
GlaxoSmithKline (GSK) - Cash on Hand
Cash on Hand as of March 2024 : $5.17 B
According to GlaxoSmithKline's latest financial reports the company has $5.17 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
GlaxoSmithKline - Cash on Hand chart (from 2001 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $6.35 B | -31.7% |
| 2022-12-31 | $9.30 B | 66.71% |
| 2021-12-31 | $5.58 B | -33.63% |
| 2020-12-31 | $8.41 B | 39.85% |
| 2019-12-31 | $6.01 B | 19.7% |
| 2018-12-31 | $5.02 B | -4.96% |
| 2017-12-31 | $5.28 B | -14.15% |
| 2016-12-31 | $6.15 B | -29.64% |
| 2015-12-31 | $8.75 B | 27.54% |
| 2014-12-31 | $6.86 B | -25.72% |
| 2013-12-31 | $9.23 B | 34% |
| 2012-12-31 | $6.89 B | -24.65% |
| 2011-12-31 | $9.14 B | -5.04% |
| 2010-12-31 | $9.63 B | -14.24% |
| 2009-12-31 | $11.23 B | 11.57% |
| 2008-12-31 | $10.06 B | 11.72% |
| 2007-12-31 | $9.01 B | 50.99% |
| 2006-12-31 | $5.96 B | -33.65% |
| 2005-12-31 | $8.99 B | 17.81% |
| 2004-12-31 | $7.63 B | 23.7% |
| 2003-12-31 | $6.17 B | 99.29% |
| 2002-12-31 | $3.09 B | 6.36% |
| 2001-12-31 | $2.91 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $9.69 B | 87.33% | 🇨🇭 Switzerland |
 Pfizer PFE | $12.69 B | 145.22% | 🇺🇸 USA |
 Sanofi SNY | $9.92 B | 91.85% | 🇫🇷 France |
 Merck MRK | $7.09 B | 37.06% | 🇺🇸 USA |
 AstraZeneca AZN | $8.02 B | 55.00% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $3.22 B | -37.66% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | $0.74 B | -85.66% | 🇺🇸 USA |